Unum Therapeutics Inc (NASDAQ:UMRX)

0.5676
Delayed Data
As of May 29
 -0.0264 / -4.44%
Today’s Change
0.30
Today|||52-Week Range
3.65
-21.19%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$10.0M

Company Description

Unum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

Contact Information

Unum Therapeutics, Inc.
200 Cambridge Park Drive
Cambridge Massachusetts 02140
P:(617) 945-5576
Investor Relations:

Employees

Shareholders

Other institutional8.68%
Individual stakeholders58.06%
Mutual fund holders2.68%

Top Executives

There are no executives to display.